Skip to Content

Broadly Neutralizing Antibodies Do Not Prevent Overall HIV-1 Acquisition

THURSDAY, March 18, 2021 -- Infusion of a broadly neutralizing antibody (bnAb) does not prevent overall HIV-1 acquisition more effectively than placebo, according to a study of two trials published in the March 18 issue of the New England Journal of Medicine.

Lawrence Corey, M.D., from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues randomly assigned 2,699 at-risk cisgender men and transgender persons in the Americas and Europe in the HVTN 704/HPTN 085 trial and 1,924 at-risk women in sub-Saharan Africa in the HVTN 703/HPTN 081 trial to receive either infusions of a bnAb (VRC01; low dose [10 mg/kg] or high dose [30 mg/kg]) or placebo for 10 infusions.

The researchers found that within each trial, adverse events were similar in number and severity among the treatment groups. In the HVTN 704/HPTN 085 trial, the incidence of HIV-1 infection was 2.35 and 2.98 per 100 person-years in the pooled VRC01 groups and the placebo group, respectively (estimated prevention efficacy, 26.6 percent; 95 percent confidence interval, −11.7 to 51.8; P = 0.15); in the HVTN 703/HPTN 081 group, the corresponding incidences were 2.49 and 3.10 (estimated prevention efficacy, 8.8 percent; 95 percent confidence interval, −45.1 to 42.6; P = 0.70). In prespecified analyses pooling data across trials, the incidence of infection with VRC01-sensitive isolates was 0.20 and 0.86 per 100 person-years among VRC01 and placebo recipients, respectively (estimated prevention efficacy, 75.4 percent; 95 percent confidence interval, 45.5 to 88.9).

"Passive immunization with VRC01 indeed protected against acquisition of HIV-1, but only against viruses that were highly sensitive to the antibody. And even for these sensitive viruses, the protection was not absolute," write the authors of an accompanying editorial.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

© 2021 HealthDay. All rights reserved.

Read this next

Grandmaternal DDT Exposure Tied to Granddaughter Early Menarche, Obesity

FRIDAY, April 16, 2021 -- Grandmaternal perinatal serum dichlorodiphenyltrichloroethane (DDT) is associated with granddaughter adult obesity and early menarche, according to a...

Brain Activity May Play Role in 'Broken Heart Syndrome'

FRIDAY, April 16, 2021 -- Researchers may have uncovered potential mechanisms contributing to "broken heart syndrome," according to a study published online March 26 in the...

Response to One COVID-19 Vaccine Dose Strong in Previously Infected

FRIDAY, April 16, 2021 -- For persons with a history of previous infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the neutralizing antibody titer is...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.